Please login to the form below

Not currently logged in
Email:
Password:

Finland's Faron Pharmaceuticals appoints new medical director

Dr Matti Karvonen brings experience from Roche, Biogen and Novartis

Faron Pharmaceuticals Dr Matti KarvonenDr Matti Karvonen has moved from Roche to join Finland's Faron Pharmaceuticals as its new medical director.

He previously served as Roche's European medical lead and prior to that held roles with Novartis and Biogen, as well as several consultancies.

Dr Karvonen has a background in clinical neurology and in the early part of his career he held several research positions, including as research director for the University of Turku's Clinical Research Services Turku (CRST) unit.

In his new role he will join Turku-based Faron's executive management team and oversee its drug development strategy, including its clinical programmes for Traumakine and Clevegen.

Dr Markku Jalkanen, CEO of Faron, said: “We are delighted to welcome Dr Karvonen to our ambitious executive management team. His appointment comes at an important time for Faron as we expand our clinical activities.

“Our lead drug candidate Traumakine, for the treatment of Acute Respiratory Distress Syndrome (ARDS) is now in a pan-European phase III INTEREST trial, while clinical development for Clevegen, our novel cancer immunotherapy drug candidate is under active planning.”

13th May 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics